New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use*; D004224:Diterpenes; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000978:Antiparkinson Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D018491:Dopamine Agonists; D009942:Organometallic Compounds; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C508887:retapamulin; C047508:rotigotine; C002791:bismuth tripotassium dicitrate